Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 506

1.

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs.

Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, Ansell S, Du X, Hope MJ, Madden TD, Mui BL, Semple SC, Tam YK, Ciufolini M, Witzigmann D, Kulkarni JA, van der Meel R, Cullis PR.

Nat Nanotechnol. 2019 Dec;14(12):1084-1087. doi: 10.1038/s41565-019-0591-y. No abstract available.

PMID:
31802031
2.

The Immune Landscape and Response to Immune Checkpoint Blockade Therapy in Lymphoma.

Kline J, Godfrey J, Ansell SM.

Blood. 2019 Dec 2. pii: blood.2019000847. doi: 10.1182/blood.2019000847. [Epub ahead of print]

PMID:
31790142
3.

IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.

Sidana S, Larson DP, Greipp PT, He R, McPhail ED, Dispenzieri A, Murray DL, Dasari S, Ansell SM, Muchtar E, Gonsalves WI, Kourelis TV, Ramirez-Alvarado M, Kapoor P, Rajkumar SV, Lacy MQ, Buadi FK, Leung N, Kyle RA, Kumar SK, King RL, Gertz MA.

Leukemia. 2019 Nov 28. doi: 10.1038/s41375-019-0667-6. [Epub ahead of print]

PMID:
31780812
4.

CAR T-cells: Driving in the Fast Lane.

Ansell SM, Corradini P.

Hemasphere. 2019 Jun 4;3(3):e209. doi: 10.1097/HS9.0000000000000209. eCollection 2019 Jun. No abstract available.

5.

Association between facility volume and mortality of patients with classic Hodgkin lymphoma.

Goyal G, Tella SH, Funni S, Kommalapati A, Inselman JW, Shah ND, Go RS, Ansell SM.

Cancer. 2019 Nov 12. doi: 10.1002/cncr.32584. [Epub ahead of print]

PMID:
31714588
6.

Immunotransplant: Preventing Unintended Consequences.

Ansell SM.

Cancer Discov. 2019 Nov;9(11):1487-1489. doi: 10.1158/2159-8290.CD-19-0977.

PMID:
31676562
7.

Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis.

Fama A, Larson MC, Link BK, Habermann TM, Feldman AL, Call TG, Ansell SM, Liebow M, Xiang J, Maurer MJ, Slager SL, Nowakowski GS, Stapleton JT, Cerhan JR.

Clin Infect Dis. 2019 Oct 31. pii: ciz940. doi: 10.1093/cid/ciz940. [Epub ahead of print]

PMID:
31671178
8.

SIRPα expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma.

Chen YP, Kim HJ, Wu H, Price-Troska T, Villasboas JC, Jalali S, Feldman AL, Novak AJ, Yang ZZ, Ansell SM.

Blood Cancer J. 2019 Oct 14;9(10):84. doi: 10.1038/s41408-019-0246-0.

9.

Pembrolizumab: living up to expectations.

Ansell SM.

Blood. 2019 Oct 3;134(14):1114-1115. doi: 10.1182/blood.2019002417. No abstract available.

PMID:
31582369
10.

Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?

Novo M, Nowakowski GS, Habermann TM, Witzig TE, Micallef IN, Johnston PB, Inwards DJ, Botto B, Ristow KM, Young JR, Vitolo U, Ansell SM.

Leuk Lymphoma. 2019 Sep 26:1-10. doi: 10.1080/10428194.2019.1663422. [Epub ahead of print]

PMID:
31556355
11.

Language, Culture, and Collectivism: Uniting Coalition Partners and Promoting Holistic Health in the Menominee Nation.

Hilgendorf A, Guy Reiter A, Gauthier J, Krueger S, Beaumier K, Corn R Sr, Moore TR, Roland H, Wells A, Pollard E, Ansell S, Oshkeshequoam J, Adams A, Christens BD.

Health Educ Behav. 2019 Oct;46(1_suppl):81S-87S. doi: 10.1177/1090198119859401.

PMID:
31549556
12.

Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.

Taparra K, Liu H, Polley MY, Ristow K, Habermann TM, Ansell SM.

Leuk Lymphoma. 2019 Sep 13:1-11. doi: 10.1080/10428194.2019.1663419. [Epub ahead of print]

PMID:
31517559
13.

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.

Wang Y, Wenzl K, Manske MK, Asmann YW, Sarangi V, Greipp PT, Krull JE, Hartert K, He R, Feldman AL, Maurer MJ, Slager SL, Nowakowski GS, Habermann TM, Witzig TE, Link BK, Ansell SM, Cerhan JR, Novak AJ.

Blood Cancer J. 2019 Aug 30;9(9):73. doi: 10.1038/s41408-019-0233-5.

14.

Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.

Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, Kumar S, Manske M, Novak AJ, King R, Greipp P, Go R, Inwards D, Muchtar E, Habermann T, Witzig TE, Thompson CA, Dingli D, Lacy MQ, Leung N, Dispenzieri A, Gonsalves W, Warsame R, Kyle RA, Rajkumar V, Parikh SA, Kapoor P.

Br J Haematol. 2019 Aug 29. doi: 10.1111/bjh.16168. [Epub ahead of print]

PMID:
31468508
15.

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y.

Biol Blood Marrow Transplant. 2019 Aug 22. pii: S1083-8791(19)30529-4. doi: 10.1016/j.bbmt.2019.08.015. [Epub ahead of print] Review.

PMID:
31446199
16.

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

Din L, Sheikh M, Kosaraju N, Smedby KE, Bernatsky S, Berndt SI, Skibola CF, Nieters A, Wang S, McKay JD, Cocco P, Maynadié M, Foretová L, Staines A, Mack TM, de Sanjosé S, Vyse TJ, Padyukov L, Monnereau A, Arslan AA, Moore A, Brooks-Wilson AR, Novak AJ, Glimelius B, Birmann BM, Link BK, Stewart C, Vajdic CM, Haioun C, Magnani C, Conti DV, Cox DG, Casabonne D, Albanes D, Kane E, Roman E, Muzi G, Salles G, Giles GG, Adami HO, Ghesquières H, De Vivo I, Clavel J, Cerhan JR, Spinelli JJ, Hofmann J, Vijai J, Curtin K, Costenbader KH, Onel K, Offit K, Teras LR, Morton L, Conde L, Miligi L, Melbye M, Ennas MG, Liebow M, Purdue MP, Glenn M, Southey MC, Din M, Rothman N, Camp NJ, Wong Doo N, Becker N, Pradhan N, Bracci PM, Boffetta P, Vineis P, Brennan P, Kraft P, Lan Q, Severson RK, Vermeulen RCH, Milne RL, Kaaks R, Travis RC, Weinstein SJ, Chanock SJ, Ansell SM, Slager SL, Zheng T, Zhang Y, Benavente Y, Taub Z, Madireddy L, Gourraud PA, Oksenberg JR, Cozen W, Hjalgrim H, Khankhanian P.

Genet Epidemiol. 2019 Oct;43(7):844-863. doi: 10.1002/gepi.22242. Epub 2019 Aug 13.

PMID:
31407831
17.

An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.

Veeramani S, Blackwell SE, Thiel WH, Yang ZZ, Ansell SM, Giangrande PH, Weiner GJ.

Cancer Immunol Res. 2019 Sep;7(9):1511-1522. doi: 10.1158/2326-6066.CIR-18-0821. Epub 2019 Aug 5.

PMID:
31383650
18.

Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma.

Wang Y, Link BK, Witzig TE, Maurer MJ, Allmer C, King RL, Feldman AL, Habermann TM, Ansell SM, Slager SL, Cerhan JR, Nowakowski GS.

Blood. 2019 Oct 17;134(16):1289-1297. doi: 10.1182/blood.2019000858.

PMID:
31350266
19.

Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

Wang Y, Farooq U, Link BK, Larson MC, King RL, Maurer MJ, Allmer C, Hefazi M, Thompson CA, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Ansell SM, Cerhan JR, Nowakowski GS.

J Clin Oncol. 2019 Jul 20;37(21):1819-1827. doi: 10.1200/JCO.19.00014. Epub 2019 Jun 6.

PMID:
31170029
20.

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.

Wang Y, Maurer MJ, Larson MC, Allmer C, Feldman AL, Bennani NN, Thompson CA, Porrata LF, Habermann TM, Witzig TE, Ansell SM, Slager SL, Nowakowski GS, Cerhan JR.

Br J Haematol. 2019 Sep;186(6):820-828. doi: 10.1111/bjh.15997. Epub 2019 May 28.

PMID:
31135975

Supplemental Content

Loading ...
Support Center